Table 4. Antifungal susceptibilities of Candida spp. from colonized patients.
| Antifungal agents | Candida spp. | |||||
|---|---|---|---|---|---|---|
| C. albicans (n=116) | C. glabrata (n=18) | C. parapsilosis (n=3) | C. tropicalis (n=1) | C. krusei (n=1) | ||
| 5-Flucytosine | ||||||
| n (%) | S | 112 (96.6) | 18 (100.0) | 3 (100.0) | 1 (100.0) | – |
| SDD | – | – | – | – | – | |
| R | 4 (3.4) | – | – | – | 1 (100.0) | |
| Amphotericin B | ||||||
| n (%) | S | 115 (99.1) | 18 (100.0) | 3 (100.0) | 1 (100.0) | 1 (100.0) |
| SDD | – | – | – | – | – | |
| R | 1 (0.9) | – | – | – | – | |
| Fluconazole | ||||||
| n (%) | S | 105 (90.6) | 16 (88.8) | 3 (100.0) | – | – |
| SDD | 4 (3.4) | 1 (5.6) | – | 1 (100.0) | – | |
| R | 7 (6.0) | 1 (5.6) | – | – | 1 (100.0) | |
| Itraconazole | ||||||
| n (%) | S | 99 (85.3) | 7 (38.9) | 2 (66.7) | – | – |
| SDD | 8 (6.9) | 5 (27.8) | – | – | 1 (100.0) | |
| R | 9 (7.8) | 6 (33.3) | 1 (33.3) | 1 (100.0) | – | |
| Voriconazole | ||||||
| n (%) | S | 112 (96.6) | 18 (100.0) | 3 (100.0) | 1 (100.0) | 1 (100.0) |
| SDD | 1 (0.9) | – | – | – | – | |
| R | 3 (2.5) | – | – | – | – | |
The antifungal susceptibility test was carried out on the Candida isolates from phenotypic assays. Only the Candida isolates that yielded consistent Candida spp. identification results or had been confirmed by sequencing for strain identity were included.
S, susceptible; SDD, susceptible dose-dependent; R, resistant.